Cancer Genetics, Inc.â€™s (OTCQB: CGIX) (â€œCGIâ€ or the â€œCompanyâ€) wholly-owned subsidiary, Cancer Genetics Italia, S.r.l. (â€œCGI Italiaâ€), has entered into an agreement with Nikon Instruments S.p.A. (â€œNikonâ€) for the distribution of oncology-focused DNA Probes intended for fluorescence in situ hybridization (â€œFISHâ€) in the Italian market. This new partnership extends CGIâ€™s global distribution network and provides more evidence that its best-in-class cancer diagnostic technologies are becoming widely accepted in the global oncology healthcare community.
Â FISH allows for the detection of targeted DNA rearrangements commonly found in cancers, and is therefore widely used for the diagnosis, outcome prediction and clinical management of cancer patients. Characterized by a fast turnaround time, high sensitivity, and the ability to study the cell cycle at different stages, this methodology represents the leading technology in the molecular cytogenetics market. With approximately 70,000 tests performed annually in Italy, this new partnership is expected to rapidly gain market share in Italy through the offering of a complete solution, including microscopy and reagents, to cytogenetics and cancer laboratories.
Â Nikon is ranked among the top microscope manufacturers worldwide, and offers a wide line of products intended to help laboratories to deliver quality research and clinical results. Nikonâ€™s microscopes and imaging software systems, both automated and user-friendly, provide cytogenetics laboratories with solutions that improve workflow efficiency and reduce subjectivity. Combined with the CGI Italia DNA-FISH Probes, which allow for more efficient pinpointing of genetic aberrations, this full solution will allow laboratories to perform simultaneous multicolor FISH testing with complex image analysis in academic and clinical settings.
Â â€œThrough research, CGI has designed and developed a set of outstanding DNA-FISH Probes for diagnosis of genomic aberrations currently recognized as essential in clinical practice,â€ says Raju Chaganti, professor at the Memorial Sloan-Kettering Cancer Center and founder of the Company. â€œJoining hands with Nikon is a great opportunity for both companies, and it advances the cause of personalized cancer management.â€
Â â€œNikon appreciates the great opportunity to distribute CGI Italia DNA-FISH Probes in the Italian market. This partnership allows us to complete our instrumentation and consumables line for FISH applications,â€ says Cristiana Ricci of Nikon. â€œNikon has developed, especially for the Oncology/Hematology field, a microspots system to investigate FISH on a microchannel, and CGI Italiaâ€™s probes are very important to complete our full solution offer for our customers.â€
Â This partnership further enables the Companyâ€™s mission to provide clinical laboratory professionals with robustly designed products for FISH and cancer diagnostics. While focused initially on the Italian market, this partnership is expected to expand to other Western European countries. CGI estimates that over 350,000 FISH-based diagnostic tests are done annually in Western Europe.
Â About Nikon Instruments S.p.A
Nikon Instruments S.p.A., the Italian subsidiary of Nikon Corporation, Japan, was founded in 1995. The companyâ€™s principal activity is to distribute diagnostic, research and measurement instruments. The Nikon Instruments division provides products used for leading-edge research purposes in clinical, educational usage and training applications. For more information about Nikon Instruments SPA, please visitÂ http://www.nikoninstruments.com.
About Cancer Genetics Italia S.r.l.
Cancer Genetics Italia S.r.l. (â€œCGI Italiaâ€) is a wholly-owned subsidiary of Cancer Genetics Inc. (â€œCGIâ€). CGI Italia manufactures and distributes DNA-FISH Probes to the clinical and academic communities worldwide. CGI Italia, founded in 2009 by world-renowned human geneticist R.S.K. Chaganti, is now celebrating its fourth year of business, and is offering an array of high-quality products with an oncology focus. Indeed, CGI Italia offers 31 FISH Probes that are CE marked (also available as RUO â€“ â€œResearch Use Onlyâ€) and cover the most relevant FISH panels for hematological and solid tumors. It should also be noted that CGI Italia was the first to launch a CE markedÂ ALKÂ Break Apart Probe in the EU. In addition to commonly used FISH Probes, CGI Italia developed a proprietary Probe that targets chromosomal aberrations observed in HPV-associated cancers. Â We launched the FISH Based HPV-Associated Cancer Test (FHACTâ„¢) intended for cervical cancer in 2012. FHACTâ„¢ is currently available as RUO. CGI Italia news releases and other information are available on the company’s Web site at www.cancergeneticsitalia.com.
Â RedChip Companies, Inc.
Jon Cunningham, 800-733-2447, ext. 107